BLTE BELITE BIO INC

Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will be participating at the Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7, 2023, at the New York Athletic Club in New York City.

To schedule a one-on-one meeting with management, you may submit your request online via the link provided upon registration. To register for the conference, please visit .

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease and geographic atrophy in advanced dry age-related macular degeneration, in addition to specific metabolic diseases. For more information, follow us on , , , , or visit us at .

Media and Investor Relations Contact:

Jennifer Wu

Julie Fallon



EN
30/11/2023

Underlying

BLTEBELITE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BELITE BIO INC

 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory...

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant MHRA response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that United King...

15h / 44m 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Co...

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will present at the Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference hosted by VirtualInvestorConferences.com, on November 4, 2025. Details of the presentation are as follows: 10:30 ...

October 29, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Participate in the 2025 Maxim Growth Summit

Belite Bio to Participate in the 2025 Maxim Growth Summit SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will be participating in the Maxim Growth Summit on October 22, 2025. To schedule a one-on-one meeting with management, please reach out to your Maxim representative. About Belite BioBelite Bio is a clinical-stage drug developmen...

October 16, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces China NMPA Agrees to New Drug Application with Pr...

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant NMPA’s response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Center for Drug Evaluation of China’s National Medical P...

October 15, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of ...

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation in Japan for Stargardt diseaseLast subject visit completed in the pivotal Phase 3 DRAGON trial of Tinlarebant in Stargardt diseaseTopline data expected in Q4 2025 SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-sta...

September 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch